Tumor cell-mediated neovascularization and lymphangiogenesis contrive tumor progression and cancer metastasis

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1836, Issue 2, 2013, Pages 273-286

  Cao, Zhifei ^a   Shang, Bingxue ^a   Zhang, Gaochuan ^a   Miele, Lucio ^b   Sarkar, Fazlul H ^c   Wang, Zhiwei ^a,d   Zhou, Quansheng ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b UNIVERSITY OF MISSISSIPPI   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cancer metastasis; Cancer stem cells; Lymphangiogenesis; Neovascularization; Trans differentiation; Vasculogenic mimicry

Indexed keywords

ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; CD133 ANTIGEN; CD34 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MATRIX METALLOPROTEINASE; MYC PROTEIN; PAZOPANIB; RECOMBINANT ENDOSTATIN; SORAFENIB; SUNITINIB; VANDETANIB; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANTIANGIOGENIC THERAPY; BREAST CANCER; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STEM CELL; CELL TRANSDIFFERENTIATION; COLON CANCER; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; GLIOMA; HUMAN; HYPOXIA; KIDNEY CANCER; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHANGIOGENESIS; LYMPHOMA; METASTASIS; NONHUMAN; ONCOGENE; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SENTINEL LYMPH NODE; SIGNAL TRANSDUCTION; STEM CELL NICHE; SURVIVAL RATE; TUMOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR RECURRENCE; TUMOR VASCULARIZATION;

CANCER METASTASIS; CANCER STEM CELLS; LYMPHANGIOGENESIS; NEOVASCULARIZATION; TRANS-DIFFERENTIATION; VASCULOGENIC MIMICRY;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; HUMANS; LYMPHANGIOGENESIS; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84882955549     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2013.08.001     Document Type: Review

References (228)

1. Carmeliet P., Jain R.K. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011, 473:298-307.
2. Gomes F.G., Nedel F., Alves A.M., Nor J.E., Tarquinio S.B. Tumor angiogenesis and lymphangiogenesis: tumor/endothelial crosstalk and cellular/microenvironmental signaling mechanisms. Life Sci. 2013, 92:101-107.
3. Moserle L., Casanovas O. Anti-angiogenesis and metastasis: a tumour and stromal cell alliance. J. Intern. Med. 2013, 273:128-137.
4. Liu W., Xu J., Wang M., Wang Q., Bi Y., Han M. Tumor-derived vascular endothelial growth factor (VEGF)-a facilitates tumor metastasis through the VEGF-VEGFR1 signaling pathway. Int. J. Oncol. 2011, 39:1213-1220.
5. Masoumi M.S., Amini A., Morris D.L., Pourgholami M.H. Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer. Cancer Metastasis Rev. 2012, 31:143-162.
6. van Zijl F., Krupitza G., Mikulits W. Initial steps of metastasis: cell invasion and endothelial transmigration. Mutat. Res. 2011, 728:23-34.
7. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
8. Christiansen A., Detmar M. Lymphangiogenesis and cancer. Genes Cancer 2011, 2:1146-1158.
9. Alitalo A., Detmar M. Interaction of tumor cells and lymphatic vessels in cancer progression. Oncogene 2012, 31:4499-4508.
10. Al-Rawi M.A., Jiang W.G. Lymphangiogenesis and cancer metastasis. Front. Biosci. 2011, 16:723-739.
11. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971, 285:1182-1186.
12. Loges S., Mazzone M., Hohensinner P., Carmeliet P. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 2009, 15:167-170.
13. Paez-Ribes M., Allen E., Hudock J., Takeda T., Okuyama H., Vinals F., Inoue M., Bergers G., Hanahan D., Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15:220-231.
14. Ebos J.M., Lee C.R., Cruz-Munoz W., Bjarnason G.A., Christensen J.G., Kerbel R.S. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009, 15:232-239.
15. Ebos J.M., Kerbel R.S. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat. Rev. Clin. Oncol. 2011, 8:210-221.
16. De Bock K., Mazzone M., Carmeliet P. Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not. Nat. Rev. Clin. Oncol. 2011, 8:393-404.
17. Johannessen T.C., Wagner M., Straume O., Bjerkvig R., Eikesdal H.P. Tumor vasculature: the Achilles' heel of cancer. Expert Opin. Ther. Targets 2013, 17:7-20.
18. Qin L., Bromberg-White J.L., Qian C.N. Opportunities and challenges in tumor angiogenesis research: back and forth between bench and bed. Adv. Cancer Res. 2012, 113:191-239.
19. Shojaei F. Anti-angiogenesis therapy in cancer: current challenges and future perspectives. Cancer Lett. 2012, 320:130-137.
20. Nagy J.A., Dvorak H.F. Heterogeneity of the tumor vasculature: the need for new tumor blood vessel type-specific targets. Clin. Exp. Metastasis 2012, 29:657-662.
21. Maniotis A.J., Folberg R., Hess A., Seftor E.A., Gardner L.M., Pe'er J., Trent J.M., Meltzer P.S., Hendrix M.J. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am. J. Pathol. 1999, 155:739-752.
22. Hendrix M.J., Seftor E.A., Hess A.R., Seftor R.E. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat. Rev. Cancer 2003, 3:411-421.
23. Wang W., Lin P., Han C., Cai W., Zhao X., Sun B. Vasculogenic mimicry contributes to lymph node metastasis of laryngeal squamous cell carcinoma. J. Exp. Clin. Cancer Res. 2010, 29:60.
24. Liu R., Yang K., Meng C., Zhang Z., Xu Y. Vasculogenic mimicry is a marker of poor prognosis in prostate cancer. Cancer Biol. Ther. 2012, 13:527-533.
25. Wang R., Chadalavada K., Wilshire J., Kowalik U., Hovinga K.E., Geber A., Fligelman B., Leversha M., Brennan C., Tabar V. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010, 468:829-833.
26. Ricci-Vitiani L., Pallini R., Biffoni M., Todaro M., Invernici G., Cenci T., Maira G., Parati E.A., Stassi G., Larocca L.M., De Maria R. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010, 468:824-828.
27. Hida K., Hida Y., Amin D.N., Flint A.F., Panigrahy D., Morton C.C., Klagsbrun M. Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res. 2004, 64:8249-8255.
28. Hida K., Klagsbrun M. A new perspective on tumor endothelial cells: unexpected chromosome and centrosome abnormalities. Cancer Res. 2005, 65:2507-2510.
29. Holash J., Maisonpierre P.C., Compton D., Boland P., Alexander C.R., Zagzag D., Yancopoulos G.D., Wiegand S.J. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999, 284:1994-1998.
30. Leenders W.P., Kusters B., de Waal R.M. Vessel co-option: how tumors obtain blood supply in the absence of sprouting angiogenesis. Endothelium 2002, 9:83-87.
31. Kucera T., Lammert E. Ancestral vascular tube formation and its adoption by tumors. Biol. Chem. 2009, 390:985-994.
32. Hendrix M.J., Seftor E.A., Meltzer P.S., Gardner L.M., Hess A.R., Kirschmann D.A., Schatteman G.C., Seftor R.E. Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:8018-8023.
33. Zhang S., Li M., Zhang D., Xu S., Wang X., Liu Z., Zhao X., Sun B. Hypoxia influences linearly patterned programmed cell necrosis and tumor blood supply patterns formation in melanoma. Lab. Invest. 2009, 89:575-586.
34. van Beurden A., Schmitz R.F., van Dijk C.M., Baeten C.I. Periodic acid Schiff loops and blood lakes associated with metastasis in cutaneous melanoma. Melanoma Res. 2012, 22:424-429.
35. Sood A.K., Seftor E.A., Fletcher M.S., Gardner L.M., Heidger P.M., Buller R.E., Seftor R.E., Hendrix M.J. Molecular determinants of ovarian cancer plasticity. Am. J. Pathol. 2001, 158:1279-1288.
36. Sood A.K., Fletcher M.S., Zahn C.M., Gruman L.M., Coffin J.E., Seftor E.A., Hendrix M.J. The clinical significance of tumor cell-lined vasculature in ovarian carcinoma: implications for anti-vasculogenic therapy. Cancer Biol. Ther. 2002, 1:661-664.
37. Shirakawa K., Wakasugi H., Heike Y., Watanabe I., Yamada S., Saito K., Konishi F. Vasculogenic mimicry and pseudo-comedo formation in breast cancer. Int. J. Cancer 2002, 99:821-828.
38. Buijs J.T., Cleton A.M., Smit V.T., Lowik C.W., Gv P.S.E.P. Prognostic significance of periodic acid-Schiff-positive patterns in primary breast cancer and its lymph node metastases. Breast Cancer Res. Treat. 2004, 84:117-130.
39. Liu T., Sun B., Zhao X., Gu Q., Dong X., Yao Z., Zhao N., Chi J., Liu N., Sun R., Ma Y. HER2/neu expression correlates with vasculogenic mimicry in invasive breast carcinoma. J. Cell. Mol. Med. 2013, 17:116-122.
40. Liu T.J., Sun B.C., Zhao X.L., Zhao X.M., Sun T., Gu Q., Yao Z., Dong X.Y., Zhao N., Liu N. CD133+ cells with cancer stem cell characteristics associates with vasculogenic mimicry in triple-negative breast cancer. Oncogene 2013, 32:544-553.
41. Cai X.S., Jia Y.W., Mei J., Tang R.Y. Tumor blood vessels formation in osteosarcoma: vasculogenesis mimicry. Chin. Med. J. 2004, 117:94-98.
42. Sharma N., Seftor R.E., Seftor E.A., Gruman L.M., Heidger P.M., Cohen M.B., Lubaroff D.M., Hendrix M.J. Prostatic tumor cell plasticity involves cooperative interactions of distinct phenotypic subpopulations: role in vasculogenic mimicry. Prostate 2002, 50:189-201.
43. Sun B., Zhang S., Zhao X., Zhang W., Hao X. Vasculogenic mimicry is associated with poor survival in patients with mesothelial sarcomas and alveolar rhabdomyosarcomas. Int. J. Oncol. 2004, 25:1609-1614.
44. Fujimoto A., Onodera H., Mori A., Nagayama S., Yonenaga Y., Tachibana T. Tumour plasticity and extravascular circulation in ECV304 human bladder carcinoma cells. Anticancer. Res. 2006, 26:59-69.
45. Liu Z., Sun B., Qi L., Li H., Gao J., Leng X. Zinc finger E-box binding homeobox 1 promotes vasculogenic mimicry in colorectal cancer through induction of epithelial-to-mesenchymal transition. Cancer Sci. 2012, 103:813-820.
46. Baeten C.I., Hillen F., Pauwels P., de Bruine A.P., Baeten C.G. Prognostic role of vasculogenic mimicry in colorectal cancer. Dis. Colon Rectum 2009, 52:2028-2035.
47. Sun B., Qie S., Zhang S., Sun T., Zhao X., Gao S., Ni C., Wang X., Liu Y., Zhang L. Role and mechanism of vasculogenic mimicry in gastrointestinal stromal tumors. Hum. Pathol. 2008, 39:444-451.
48. Li M., Gu Y., Zhang Z., Zhang S., Zhang D., Saleem A.F., Zhao X., Sun B. Vasculogenic mimicry: a new prognostic sign of gastric adenocarcinoma. Pathol. Oncol. Res. 2010, 16:259-266.
49. Jiang J., Liu W., Guo X., Zhang R., Zhi Q., Ji J., Zhang J., Chen X., Li J., Zhang J., Gu Q., Liu B., Zhu Z., Yu Y. IRX1 influences peritoneal spreading and metastasis via inhibiting BDKRB2-dependent neovascularization on gastric cancer. Oncogene 2011, 30:4498-4508.
50. Liu W.B., Xu G.L., Jia W.D., Li J.S., Ma J.L., Chen K., Wang Z.H., Ge Y.S., Ren W.H., Yu J.H., Wang W., Wang X.J. Prognostic significance and mechanisms of patterned matrix vasculogenic mimicry in hepatocellular carcinoma. Med. Oncol. 2011, 28(Suppl. 1):S228-238.
51. Sun B., Zhang S., Zhang D., Du J., Guo H., Zhao X., Zhang W., Hao X. Vasculogenic mimicry is associated with high tumor grade, invasion and metastasis, and short survival in patients with hepatocellular carcinoma. Oncol. Rep. 2006, 16:693-698.
52. Wu S., Yu L., Wang D., Zhou L., Cheng Z., Chai D., Ma L., Tao Y. Aberrant expression of CD133 in non-small cell lung cancer and its relationship to vasculogenic mimicry. BMC Cancer 2012, 12:535.
53. Wu S., Yu L., Cheng Z., Song W., Zhou L., Tao Y. Expression of maspin in non-small cell lung cancer and its relationship to vasculogenic mimicry. J. Huazhong Univ. Sci. Technol. Med. Sci. 2012, 32:346-352.
54. Seftor E.A., Meltzer P.S., Kirschmann D.A., Pe'er J., Maniotis A.J., Trent J.M., Folberg R., Hendrix M.J. Molecular determinants of human uveal melanoma invasion and metastasis. Clin. Exp. Metastasis 2002, 19:233-246.
55. Zhao H., Gu X.M. Study on vasculogenic mimicry in malignant esophageal stromal tumors. World J. Gastroenterol. 2008, 14:2430-2433.
56. Lin P., Wang W., Sun B.C., Cai W.J., Li L., Lu H.H., Han C.R., Zhang J.M. Vasculogenic mimicry is a key prognostic factor for laryngeal squamous cell carcinoma: a new pattern of blood supply. Chin. Med. J. 2012, 125:3445-3449.
57. Liu S.Y., Chang L.C., Pan L.F., Hung Y.J., Lee C.H., Shieh Y.S. Clinicopathologic significance of tumor cell-lined vessel and microenvironment in oral squamous cell carcinoma. Oral Oncol. 2008, 44:277-285.
58. Liu X.M., Zhang Q.P., Mu Y.G., Zhang X.H., Sai K., Pang J.C., Ng H.K., Chen Z.P. Clinical significance of vasculogenic mimicry in human gliomas. J. Neurooncol. 2011, 105:173-179.
59. Wang S.Y., Yu L., Ling G.Q., Xiao S., Sun X.L., Song Z.H., Liu Y.J., Jiang X.D., Cai Y.Q., Ke Y.Q. Vasculogenic mimicry and its clinical significance in medulloblastoma. Cancer Biol. Ther. 2012, 13:341-348.
60. Vartanian A.A., Stepanova E.V., Gutorov S.L., ESh S., Grigorieva I.N., Sokolova I.N., Baryshnikov A.Y., Lichinitser M.R. Prognostic significance of periodic acid-Schiff-positive patterns in clear cell renal cell carcinoma. Can. J. Urol. 2009, 16:4726-4732.
61. Cao Z., Bao M., Miele L., Sarkar F.H., Wang Z., Zhou Q. Tumor vasculogenic mimicry is associated with poor prognosis of human cancer patients: a systemic review and meta-analysis. Eur. J. Cancer 2013, in press.
62. Alameddine R.S., Otrock Z.K., Awada A., Shamseddine A. Crosstalk between HER2 signaling and angiogenesis in breast cancer: molecular basis, clinical applications and challenges. Curr. Opin. Oncol. 2013, 25:313-324.
63. Guillot A., Levy A., Pacaut C., Collard O., Massard C., Merrouche Y., Magne N. Reappraisal of the role of bevacizumab in the therapeutic strategy in advanced renal cell carcinoma. Clin. Genitourin. Cancer 2012, 10:147-152.
64. Sun T., Zhao N., Zhao X.L., Gu Q., Zhang S.W., Che N., Wang X.H., Du J., Liu Y.X., Sun B.C. Expression and functional significance of Twist1 in hepatocellular carcinoma: its role in vasculogenic mimicry. Hepatology 2010, 51:545-556.
65. Chou M.T., Anthony J., Bjorge J.D., Fujita D.J. The von Hippel-Lindau tumor suppressor protein is destabilized by Src: implications for tumor angiogenesis and progression. Genes Cancer 2010, 1:225-238.
66. Midulla M., Verma R., Pignatelli M., Ritter M.A., Courtenay-Luck N.S., George A.J. Source of oncofetal ED-B-containing fibronectin: implications of production by both tumor and endothelial cells. Cancer Res. 2000, 60:164-169.
67. Ventura E., Sassi F., Parodi A., Balza E., Borsi L., Castellani P., Carnemolla B., Zardi L. Alternative splicing of the angiogenesis associated extra-domain B of fibronectin regulates the accessibility of the B-C loop of the type III repeat 8. PLoS One 2010, 5:e9145.
68. Vestweber D. VE-cadherin: the major endothelial adhesion molecule controlling cellular junctions and blood vessel formation. Arterioscler. Thromb. Vasc. Biol. 2008, 28:223-232.
69. Wang L., O'Leary H., Fortney J., Gibson L.F. Ph+/VE-cadherin+ identifies a stem cell like population of acute lymphoblastic leukemia sustained by bone marrow niche cells. Blood 2007, 110:3334-3344.
70. Alvero A.B., Fu H.H., Holmberg J., Visintin I., Mor L., Marquina C.C., Oidtman J., Silasi D.A., Mor G. Stem-like ovarian cancer cells can serve as tumor vascular progenitors. Stem Cells 2009, 27:2405-2413.
71. Cao Z., Yu D., Fu S., Zhang G., Pan Y., Bao M., Tu J., Shang B., Guo P., Yang P., Zhou Q. Lycorine hydrochloride selectively inhibits human ovarian cancer cell proliferation and tumor neovascularization with very low toxicity. Toxicol. Lett. 2013, 218:174-185.
72. Zhang L.Z., Mei J., Qian Z.K., Cai X.S., Jiang Y., Huang W.D. The role of VE-cadherin in osteosarcoma cells. Pathol. Oncol. Res. 2010, 16:111-117.
73. Ryu K.H., Shim K.N., Jung S.A., Yoo K., Joo Y.H., Lee J.H. Significance of preoperative tissue levels of vascular-endothelial cadherin, liver-intestine cadherin and vascular endothelial growth factor in gastric cancer. Korean J. Gastroenterol. 2012, 60:229-241.
74. Fry S.A., Sinclair J., Timms J.F., Leathem A.J., Dwek M.V. A targeted glycoproteomic approach identifies cadherin-5 as a novel biomarker of metastatic breast cancer. Cancer Lett. 2013, 328:335-344.
75. Postovit L.M., Margaryan N.V., Seftor E.A., Hendrix M.J. Role of nodal signaling and the microenvironment underlying melanoma plasticity. Pigment Cell Melanoma Res. 2008, 21:348-357.
76. McAllister J.C., Zhan Q., Weishaupt C., Hsu M.Y., Murphy G.F. The embryonic morphogen, Nodal, is associated with channel-like structures in human malignant melanoma xenografts. J. Cutan. Pathol. 2010, 37(Suppl. 1):19-25.
77. Quail D.F., Walsh L.A., Zhang G., Findlay S.D., Moreno J., Fung L., Ablack A., Lewis J.D., Done S.J., Hess D.A., Postovit L.M. Embryonic protein nodal promotes breast cancer vascularization. Cancer Res. 2012, 72:3851-3863.
78. Lee C.C., Jan H.J., Lai J.H., Ma H.I., Hueng D.Y., Lee Y.C., Cheng Y.Y., Liu L.W., Wei H.W., Lee H.M. Nodal promotes growth and invasion in human gliomas. Oncogene 2010, 29:3110-3123.
79. Hueng D.Y., Lin G.J., Huang S.H., Liu L.W., Ju D.T., Chen Y.W., Sytwu H.K., Chang C., Huang S.M., Yeh Y.S., Lee H.M., Ma H.I. Inhibition of Nodal suppresses angiogenesis and growth of human gliomas. J. Neurooncol. 2011, 104:21-31.
80. Hardy K.M., Kirschmann D.A., Seftor E.A., Margaryan N.V., Postovit L.M., Strizzi L., Hendrix M.J. Regulation of the embryonic morphogen Nodal by Notch4 facilitates manifestation of the aggressive melanoma phenotype. Cancer Res. 2010, 70:10340-10350.
81. Quail D.F., Zhang G., Findlay S.D., Hess D.A., Postovit L.M. Nodal promotes invasive phenotypes via a mitogen-activated protein kinase-dependent pathway. Oncogene 2013, 10.1038/onc.2012.608.
82. Yang Y., Sun M., Wang L., Jiao B. HIFs, angiogenesis, and cancer. J. Cell. Biochem. 2013, 114:967-974.
83. Ladroue C., Carcenac R., Leporrier M., Gad S., Le H.C., Galateau-Salle F., Feunteun J., Pouyssegur J., Richard S., Gardie B. PHD2 mutation and congenital erythrocytosis with paraganglioma. N. Engl. J. Med. 2008, 359:2685-2692.
84. Mazzone M., Dettori D., de L.Oliveira R., Loges S., Schmidt T., Jonckx B., Tian Y.M., Lanahan A.A., Pollard P., de R.Almodovar C., De Smet F., Vinckier S., Aragones J., Debackere K., Luttun A., Wyns S., Jordan B., Pisacane A., Gallez B., Lampugnani M.G., Dejana E., Simons M., Ratcliffe P., Maxwell P., Carmeliet P. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 2009, 136:839-851.
85. Gao J.X. Cancer stem cells: the lessons from pre-cancerous stem cells. J. Cell. Mol. Med. 2008, 12:67-96.
86. Kwon M.J., Shin Y.K. Regulation of ovarian cancer stem cells or tumor-initiating cells. Int. J. Mol. Sci. 2013, 14:6624-6648.
87. Foster R., Buckanovich R.J., Rueda B.R. Ovarian cancer stem cells: working towards the root of stemness. Cancer Lett. 2012, LID - S0304-3835(12)00628-3 [pii]. 10.1016/j.canlet.2012.10.023.
88. Valent P., Bonnet D., Wohrer S., Andreeff M., Copland M., Chomienne C., Eaves C. Heterogeneity of neoplastic stem cells: theoretical, functional, and clinical implications. Cancer Res. 2013, 73:1037-1045.
89. Yamashita T., Wang X.W. Cancer stem cells in the development of liver cancer. J. Clin. Invest. 2013, 123:1911-1918.
90. Roy S., Majumdar A.P. Cancer stem cells in colorectal cancer: genetic and epigenetic changes. J Stem Cell Res Ther 2012, (Suppl. 7). LID - 10342 [pii].
91. Shiozawa Y., Nie B., Pienta K.J., Morgan T.M., Taichman R.S. Cancer stem cells and their role in metastasis. Pharmacol. Ther. 2013, 138:285-293.
92. Ortensi B., Setti M., Osti D., Pelicci G. Cancer stem cell contribution to glioblastoma invasiveness. Stem Cell Res. Ther. 2013, 4:18.
93. Abdullah L.N., Chow E.K. Mechanisms of chemoresistance in cancer stem cells. Clin. Transl. Med. 2013, 2:3.
94. Ogawa K., Yoshioka Y., Isohashi F., Seo Y., Yoshida K., Yamazaki H. Radiotherapy targeting cancer stem cells: current views and future perspectives. Anticancer. Res. 2013, 33:747-754.
95. Shekhani M.T., Jayanthy A.S., Maddodi N., Setaluri V. Cancer stem cells and tumor transdifferentiation: implications for novel therapeutic strategies. Am. J. Stem Cells 2013, 2:52-61.
96. Shen R., Ye Y., Chen L., Yan Q., Barsky S.H., Gao J.X. Precancerous stem cells can serve as tumor vasculogenic progenitors. PLoS One 2008, 3:e1652.
97. Zhao Y., Dong J., Huang Q., Lou M., Wang A., Lan Q. Endothelial cell transdifferentiation of human glioma stem progenitor cells in vitro. Brain Res. Bull. 2010, 82:308-312.
98. El H.S., Boisselier B., Peglion F., Rousseau A., Colin C., Idbaih A., Marie Y., Mokhtari K., Thomas J.L., Eichmann A., Delattre J.Y., Maniotis A.J., Sanson M. A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry. Brain 2010, 133:973-982.
99. Pezzolo A., Parodi F., Corrias M.V., Cinti R., Gambini C., Pistoia V. Tumor origin of endothelial cells in human neuroblastoma. J. Clin. Oncol. 2007, 25:376-383.
100. Pisacane A.M., Picciotto F., Risio M. CD31 and CD34 expression as immunohistochemical markers of endothelial transdifferentiation in human cutaneous melanoma. Cell. Oncol. 2007, 29:59-66.
101. Bruno S., Bussolati B., Grange C., Collino F., Graziano M.E., Ferrando U., Camussi G. CD133+ renal progenitor cells contribute to tumor angiogenesis. Am. J. Pathol. 2006, 169:2223-2235.
102. Matsuda K., Ohga N., Hida Y., Muraki C., Tsuchiya K., Kurosu T., Akino T., Shih S.C., Totsuka Y., Klagsbrun M., Shindoh M., Hida K. Isolated tumor endothelial cells maintain specific character during long-term culture. Biochem. Biophys. Res. Commun. 2010, 394:947-954.
103. Ohga N., Ishikawa S., Maishi N., Akiyama K., Hida Y., Kawamoto T., Sadamoto Y., Osawa T., Yamamoto K., Kondoh M., Ohmura H., Shinohara N., Nonomura K., Shindoh M., Hida K. Heterogeneity of tumor endothelial cells: comparison between tumor endothelial cells isolated from high- and low-metastatic tumors. Am. J. Pathol. 2012, 180:1294-1307.
104. Dudley A.C., Klagsbrun M. Tumor endothelial cells have features of adult stem cells. Cell Cycle 2009, 8:236-238.
105. van Beijnum J.R., Petersen K., Griffioen A.W. Tumor endothelium is characterized by a matrix remodeling signature. Front Biosci (Schol Ed) 2009, 1:216-225.
106. Wu L.Q., Zhang W.J., Niu J.X., Ye L.Y., Yang Z.H., Grau G.E., Lou J.N. Phenotypic and functional differences between human liver cancer endothelial cells and liver sinusoidal endothelial cells. J. Vasc. Res. 2008, 45:78-86.
107. Xiong Y.Q., Sun H.C., Zhang W., Zhu X.D., Zhuang P.Y., Zhang J.B., Wang L., Wu W.Z., Qin L.X., Tang Z.Y. Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells. Clin. Cancer Res. 2009, 15:4838-4846.
108. Hendrix M.J., Seftor E.A., Kirschmann D.A., Seftor R.E. Molecular biology of breast cancer metastasis. Molecular expression of vascular markers by aggressive breast cancer cells. Breast Cancer Res. 2000, 2:417-422.
109. Hida K., Hida Y., Shindoh M. Understanding tumor endothelial cell abnormalities to develop ideal anti-angiogenic therapies. Cancer Sci. 2008, 99:459-466.
110. Bussolati B., Deregibus M.C., Camussi G. Characterization of molecular and functional alterations of tumor endothelial cells to design anti-angiogenic strategies. Curr. Vasc. Pharmacol. 2010, 8:220-232.
111. Thompson W.D., Shiach K.J., Fraser R.A., McIntosh L.C., Simpson J.G. Tumours acquire their vasculature by vessel incorporation, not vessel ingrowth. J. Pathol. 1987, 151:323-332.
112. Chang Y.S., di T.E., McDonald D.M., Jones R., Jain R.K., Munn L.L. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:14608-14613.
113. Dome B., Paku S., Somlai B., Timar J. Vascularization of cutaneous melanoma involves vessel co-option and has clinical significance. J. Pathol. 2002, 197:355-362.
114. Pezzella F., Pastorino U., Tagliabue E., Andreola S., Sozzi G., Gasparini G., Menard S., Gatter K.C., Harris A.L., Fox S., Buyse M., Pilotti S., Pierotti M., Rilke F. Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am. J. Pathol. 1997, 151:1417-1423.
115. Vermeulen P.B., Colpaert C., Salgado R., Royers R., Hellemans H., Van Den Heuvel E., Goovaerts G., Dirix L.Y., Van Marck E. Liver metastases from colorectal adenocarcinomas grow in three patterns with different angiogenesis and desmoplasia. J. Pathol. 2001, 195:336-342.
116. Paku S., Kopper L., Nagy P. Development of the vasculature in "pushing-type" liver metastases of an experimental colorectal cancer. Int. J. Cancer 2005, 115:893-902.
117. Kusters B., Leenders W.P., Wesseling P., Smits D., Verrijp K., Ruiter D.J., Peters J.P., van Der Kogel A.J., de Waal R.M. Vascular endothelial growth factor-A(165) induces progression of melanoma brain metastases without induction of sprouting angiogenesis. Cancer Res. 2002, 62:341-345.
118. Zhang S., Zhang D., Wang Y., Zhao W., Guo H., Zhao X., Sun B. Morphologic research of microcirculation patterns in human and animal melanoma. Med. Oncol. 2006, 23:403-409.
119. Comsa S., Ciuculescu F., Raica M. Mesenchymal stem cell-tumor cell cooperation in breast cancer vasculogenesis. Mol. Med. Rep. 2012, 5:1175-1180.
120. Comsa S., Ciuculescu F., Henschler R., Raica M. MCF7-MSC co-culture assay: approach to assess the co-operation between MCF-7s and MSCs in tumor-induced angiogenesis. Rom. J. Morphol. Embryol. 2011, 52:1071-1076.
121. di T.E., Capen D., Haskell A., Hart J., Logie J.J., Jain R.K., McDonald D.M., Jones R., Munn L.L. Mosaic tumor vessels: cellular basis and ultrastructure of focal regions lacking endothelial cell markers. Cancer Res. 2005, 65:5740-5749.
122. Leenders W.P., Kusters B., Verrijp K., Maass C., Wesseling P., Heerschap A., Ruiter D., Ryan A., de Waal R. Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option. Clin. Cancer Res. 2004, 10:6222-6230.
123. Zhou F., Hu J., Shao J.H., Zou S.B., Shen S.L., Luo Z.Q. Metronomic chemotherapy in combination with antiangiogenic treatment induces mosaic vascular reduction and tumor growth inhibition in hepatocellular carcinoma xenografts. J. Cancer Res. Clin. Oncol. 2012, 138:1879-1890.
124. Anders M., Fehlker M., Wang Q., Wissmann C., Pilarsky C., Kemmner W., Hocker M. Microarray meta-analysis defines global angiogenesis-related gene expression signatures in human carcinomas. Mol. Carcinog. 2013, 52:29-38.
125. Braghiroli M.I., Sabbaga J., Hoff P.M. Bevacizumab: overview of the literature. Expert. Rev. Anticancer. Ther. 2012, 12:567-580.
126. Meadows K.L., Hurwitz H.I. Anti-VEGF therapies in the clinic. Cold Spring Harb. Perspect. Med. 2012, 2. (LID - a006577 [pii]). 10.1101/cshperspect.a006577.
127. Al-Husein B., Abdalla M., Trepte M., Deremer D.L., Somanath P.R. Antiangiogenic therapy for cancer: an update. Pharmacotherapy 2012, 32:1095-1111.
128. Rapisarda A., Melillo G. Role of the VEGF/VEGFR axis in cancer biology and therapy. Adv. Cancer Res. 2012, 114:237-267.
129. Potente M., Gerhardt H., Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell 2011, 146:873-887.
130. Su Y., Yang W.B., Li S., Ye Z.J., Shi H.Z., Zhou Q. Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature. PLoS One 2012, 7:e35629.
131. Cao Y., Tan A., Gao F., Liu L., Liao C., Mo Z. A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer. Int. J. Colorectal Dis. 2009, 24:677-685.
132. Cuppone F., Bria E., Vaccaro V., Puglisi F., Fabi A., Sperduti I., Carlini P., Milella M., Nistico C., Russillo M., Papaldo P., Ferretti G., Aapro M., Giannarelli D., Cognetti F. Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: meta-regression analysis of randomized trials. J. Exp. Clin. Cancer Res. 2011, 30:54.
133. Wagner A.D., Thomssen C., Haerting J., Unverzagt S. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer. Cochrane Database Syst. Rev. 2012, 7. (CD008941).
134. Petrelli F., Barni S. Bevacizumab in advanced breast cancer: an opportunity as second-line therapy. Med. Oncol. 2012, 29:1-4.
135. Collinson F.J., Seligmann J., Perren T.J. Ovarian cancer: advances in first-line treatment strategies with a particular focus on anti-angiogenic agents. Curr. Oncol. Rep. 2012, 14:509-518.
136. Heitz F., Harter P., Barinoff J., Beutel B., Kannisto P., Grabowski J.P., Heitz J., Kurzeder C., Du Bois B.A. Bevacizumab in the treatment of ovarian cancer. Adv. Ther. 2012, 29:723-735.
137. Gaitskell K., Martinek I., Bryant A., Kehoe S., Nicum S., Morrison J. Angiogenesis inhibitors for the treatment of ovarian cancer. Cochrane Database Syst Rev 2011, 9:CD007930. 10.1002/14651858.CD007930.
138. Bevacizumab, advanced-stage ovarian cancer Yet another oncological indication, but still best to avoid using this drug. Prescrire Int. 2013, 22:64-67.
139. Robles I.L., Hambardzumyan D., Nakano I., Gladson C.L., Ahluwalia M.S. Therapeutic targeting of VEGF in the treatment of glioblastoma. Expert Opin. Ther. Targets 2012, 16:973-984.
140. Rinne M.L., Lee E.Q., Nayak L., Norden A.D., Beroukhim R., Wen P.Y., Reardon D.A. Update on bevacizumab and other angiogenesis inhibitors for brain cancer. Expert Opin. Emerg. Drugs 2013, 18:137-153.
141. Cea V., Sala C., Verpelli C. Antiangiogenic therapy for glioma. J. Signal Transduct. 2012, 2012:483040.
142. Ganjoo K., Hong F., Horning S.J., Gascoyne R.D., Natkunam Y., Swinnen L.J., Habermann T.M., Kahl B.S., Advani R.H. Bevacizumab and CHOP (A-CHOP) in Combination for Patients with Peripheral T-cell or Natural Killer Cell Neoplasms: An Eastern Cooperative Group Study (E2404) 2013, Leuk, Lymphoma.
143. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., Ferrara N., Fyfe G., Rogers B., Ross R., Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004, 350:2335-2342.
144. Fuchs C.S., Marshall J., Mitchell E., Wierzbicki R., Ganju V., Jeffery M., Schulz J., Richards D., Soufi-Mahjoubi R., Wang B., Barrueco J. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J. Clin. Oncol. 2007, 25:4779-4786.
145. Cartwright T.H., Yim Y.M., Yu E., Chung H., Halm M., Forsyth M. Survival outcomes of bevacizumab beyond progression in metastatic colorectal cancer patients treated in US community oncology. Clin. Colorectal Cancer 2012, 11:238-246.
146. Galfrascoli E., Piva S., Cinquini M., Rossi A., La Verde N., Bramati A., Moretti A., Manazza A., Damia G., Torri V., Muserra G., Farina G., Garassino M.C. Risk/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis. Dig. Liver Dis. 2011, 43:286-294.
147. Grothey A., Allegra C. Antiangiogenesis therapy in the treatment of metastatic colorectal cancer. Ther. Adv. Med. Oncol. 2012, 4:301-319.
148. Tassinari D., Sartori S., Papi M., Drudi F., Castellani C., Carloni F., Tombesi P., Lazzari-Agli L. Bevacizumab in the treatment of advanced, non-squamous non-small cell lung cancer: an evidence-based approach. Oncology 2011, 80:350-358.
149. Macedo L.T., da C.L.A.B., Sasse A.D. Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups. BMC Cancer 2012, 12:89.
150. Stremitzer S., Stift J., Gruenberger B., Tamandl D., Aschacher T., Wolf B., Wrba F., Gruenberger T. KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab. Br. J. Surg. 2012, 99:1575-1582.
151. Xiao Y.Y., Zhan P., Yuan D.M., Liu H.B., Lv T.F., Song Y., Shi Y. Chemotherapy plus multitargeted antiangiogenic tyrosine kinase inhibitors or chemotherapy alone in advanced NSCLC: a meta-analysis of randomized controlled trials. Eur. J. Clin. Pharmacol. 2013, 69:151-159.
152. Sandomenico C., Costanzo R., Carillio G., Piccirillo M.C., Montanino A., Di M.M., Rocco G., Normanno N., Perrone F., Morabito A. Bevacizumab in non small cell lung cancer: development, current status and issues. Curr. Med. Chem. 2012, 19:961-971.
153. Yang K., Wang Y.J., Chen X.R., Chen H.N. Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a meta-analysis. Clin. Drug Investig. 2010, 30:229-241.
154. Giantonio B.J., Catalano P.J., Meropol N.J., O'Dwyer P.J., Mitchell E.P., Alberts S.R., Schwartz M.A., Benson A.B. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. 2007, 25:1539-1544.
155. Saltz L.B., Clarke S., Diaz-Rubio E., Scheithauer W., Figer A., Wong R., Koski S., Lichinitser M., Yang T.S., Rivera F., Couture F., Sirzen F., Cassidy J. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J. Clin. Oncol. 2008, 26:2013-2019.
156. Tebbutt N.C., Wilson K., Gebski V.J., Cummins M.M., Zannino D., van Hazel G.A., Robinson B., Broad A., Ganju V., Ackland S.P., Forgeson G., Cunningham D., Saunders M.P., Stockler M.R., Chua Y., Zalcberg J.R., Simes R.J., Price T.J. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J. Clin. Oncol. 2010, 28:3191-3198.
157. Albini A., Tosetti F., Li V.W., Noonan D.M., Li W.W. Cancer prevention by targeting angiogenesis. Nat. Rev. Clin. Oncol. 2012, 9:498-509.
158. Sitohy B., Nagy J.A., Dvorak H.F. Anti-VEGF/VEGFR therapy for cancer: reassessing the target. Cancer Res. 2012, 72:1909-1914.
159. Wu J.M., Staton C.A. Anti-angiogenic drug discovery: lessons from the past and thoughts for the future. Expert Opin. Drug Discov. 2012, 7:723-743.
160. Giuliano S., Pages G. Mechanisms of resistance to anti-angiogenesis therapies. Biochimie 2013, 95:1110-1119.
161. Hida K., Akiyama K., Ohga N., Maishi N., Hida Y. Tumour endothelial cells acquire drug resistance in a tumour microenvironment. J. Biochem. 2013, 153:243-249.
162. Chen C.T., Hung M.C. Beyond anti-VEGF: dual-targeting antiangiogenic and antiproliferative therapy. Am. J. Transl. Res. 2013, 5:393-403.
163. Zhang S., Zhang D., Sun B. Vasculogenic mimicry: current status and future prospects. Cancer Lett. 2007, 254:157-164.
164. Patenaude A., Parker J., Karsan A. Involvement of endothelial progenitor cells in tumor vascularization. Microvasc. Res. 2010, 79:217-223.
165. Liu J., Huang J., Yao W.Y., Ben Q.W., Chen D.F., He X.Y., Li L., Yuan Y.Z. The origins of vacularization in tumors. Front. Biosci. 2012, 17:2559-2565.
166. Patan S., Munn L.L., Jain R.K. Intussusceptive microvascular growth in a human colon adenocarcinoma xenograft: a novel mechanism of tumor angiogenesis. Microvasc. Res. 1996, 51:260-272.
167. De Spiegelaere W., Casteleyn C., Van den Broeck W., Plendl J., Bahramsoltani M., Simoens P., Djonov V., Cornillie P. Intussusceptive angiogenesis: a biologically relevant form of angiogenesis. J. Vasc. Res. 2012, 49:390-404.
168. Bottsford-Miller J.N., Coleman R.L., Sood A.K. Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies. J. Clin. Oncol. 2012, 30:4026-4034.
169. Ribatti D. Cancer stem cells and tumor angiogenesis. Cancer Lett. 2012, 321:13-17.
170. Lin S.P., Lee Y.T., Yang S.H., Miller S.A., Chiou S.H., Hung M.C., Hung S.C. Colon cancer stem cells resist antiangiogenesis therapy-induced apoptosis. Cancer Lett. 2013, 328:226-234.
171. Mao X.G., Xue X.Y., Wang L., Zhang X., Yan M., Tu Y.Y., Lin W., Jiang X.F., Ren H.G., Zhang W., Song S.J. CDH5 is specifically activated in glioblastoma stemlike cells and contributes to vasculogenic mimicry induced by hypoxia. Neuro Oncol. 2013, 15:865-879.
172. Saharinen P., Eklund L., Pulkki K., Bono P., Alitalo K. VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol. Med. 2011, 17:347-362.
173. Otrock Z.K., Hatoum H.A., Awada A.H., Ishak R.S., Shamseddine A.I. Hypoxia-inducible factor in cancer angiogenesis: structure, regulation and clinical perspectives. Crit. Rev. Oncol. Hematol. 2009, 70:93-102.
174. Osinsky S., Zavelevich M., Vaupel P. Tumor hypoxia and malignant progression. Exp. Oncol. 2009, 31:80-86.
175. Conley S.J., Gheordunescu E., Kakarala P., Newman B., Korkaya H., Heath A.N., Clouthier S.G., Wicha M.S. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:2784-2789.
176. Chau C.H., Figg W.D. Angiogenesis inhibitors increase tumor stem cells. Cancer Biol. Ther. 2012, 13:586-587.
177. Qu B., Guo L., Ma J., Lv Y. Antiangiogenesis therapy might have the unintended effect of promoting tumor metastasis by increasing an alternative circulatory system. Med. Hypotheses 2010, 74:360-361.
178. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. 2001, 7:987-989.
179. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
180. Carmeliet P., Jain R.K. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat. Rev. Drug Discov. 2011, 10:417-427.
181. Molinari A.J., Pozzi E.C., Monti H.A., Heber E.M., Garabalino M.A., Thorp S.I., Miller M., Itoiz M.E., Aromando R.F., Nigg D.W., Trivillin V.A., Schwint A.E. Tumor blood vessel "normalization" improves the therapeutic efficacy of boron neutron capture therapy (BNCT) in experimental oral cancer. Radiat. Res. 2012, 177:59-68.
182. Chauhan V.P., Stylianopoulos T., Martin J.D., Popovic Z., Chen O., Kamoun W.S., Bawendi M.G., Fukumura D., Jain R.K. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat. Nanotechnol. 2012, 7:383-388.
183. Goel S., Duda D.G., Xu L., Munn L.L., Boucher Y., Fukumura D., Jain R.K. Normalization of the vasculature for treatment of cancer and other diseases. Physiol. Rev. 2011, 91:1071-1121.
184. Sato Y. Persistent vascular normalization as an alternative goal of anti-angiogenic cancer therapy. Cancer Sci. 2011, 102:1253-1256.
185. Ribatti D. Vascular normalization: a real benefit. Cancer Chemother. Pharmacol. 2011, 68:275-278.
186. Shang B., Cao Z., Zhou Q. Progress in tumor vascular normalization for anticancer therapy: challenges and perspectives. Front. Med. 2012, 6:67-78.
187. Bottos A., Bardelli A. Oncogenes and angiogenesis: a way to personalize anti-angiogenic therapy. Cell. Mol. Life Sci. 2013, Epub ahead of print, PMID: 23685900.
188. Ozasa R., Ohno J., Iwahashi T., Taniguchi K. Tumor-induced lymphangiogenesis in cervical lymph nodes in oral melanoma-bearing mice. J. Exp. Clin. Cancer Res. 2012, 31:83.
189. Cao Y., Zhong W. Tumor-derived lymphangiogenic factors and lymphatic metastasis. Biomed. Pharmacother. 2007, 61:534-539.
190. You L., Wu M., Chen Y., Xu G., Wei J., Li Q., Song A., Zhao L., Li S., Han Z., Zhou J., Lu Y., Wang S., Ma D., Meng L. Isolation and characterization of lymphatic endothelial cells from human glossal lymphangioma. Oncol. Rep. 2010, 23:105-111.
191. Zhuang Z., Jian P., Longjiang L., Bo H., Hongwei Z. Identification of oral cancer cell-induced changes in gene expression profile of lymphatic endothelial cell. Cancer Invest. 2008, 26:1002-1007.
192. Fiedler U., Christian S., Koidl S., Kerjaschki D., Emmett M.S., Bates D.O., Christofori G., Augustin H.G. The sialomucin CD34 is a marker of lymphatic endothelial cells in human tumors. Am. J. Pathol. 2006, 168:1045-1053.
193. Werchau S., Toberer F., Enk A., Dammann R., Helmbold P. Merkel cell carcinoma induces lymphatic microvessel formation. J. Am. Acad. Dermatol. 2012, 67:215-225.
194. Swoboda A., Schanab O., Tauber S., Bilban M., Berger W., Petzelbauer P., Mikula M. MET expression in melanoma correlates with a lymphangiogenic phenotype. Hum. Mol. Genet. 2012, 21:3387-3396.
195. Tawada M., Hayashi S., Osada S., Nakashima S., Yoshida K. Human gastric cancer organizes neighboring lymphatic vessels via recruitment of bone marrow-derived lymphatic endothelial progenitor cells. J. Gastroenterol. 2012, 47:1057-1060.
196. Cheng P., Jin G., Hu X., Shi M., Zhang Y., Liu R., Zhou Y., Shao C., Zheng J., Zhu M. Analysis of tumor-induced lymphangiogenesis and lymphatic vessel invasion of pancreatic carcinoma in the peripheral nerve plexus. Cancer Sci. 2012, 103:1756-1763.
197. Semenza G.L. Cancer-stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasis. Oncogene 2012, 10.1038/onc.2012.578.
198. Kurahara H., Takao S., Maemura K., Mataki Y., Kuwahata T., Maeda K., Sakoda M., Iino S., Ishigami S., Ueno S., Shinchi H., Natsugoe S. M2-polarized tumor-associated macrophage infiltration of regional lymph nodes is associated with nodal lymphangiogenesis and occult nodal involvement in pN0 pancreatic cancer. Pancreas 2013, 42:155-159.
199. Ran S., Montgomery K.E. Macrophage-mediated lymphangiogenesis: the emerging role of macrophages as lymphatic endothelial progenitors. Cancers (Basel) 2012, 4:618-657.
200. Conrad C., Niess H., Huss R., Huber S., von L.I., Nelson P.J., Ott H.C., Jauch K.W., Bruns C.J. Multipotent mesenchymal stem cells acquire a lymphendothelial phenotype and enhance lymphatic regeneration in vivo. Circulation 2009, 119:281-289.
201. Zoccoli A., Iuliani M., Pantano F., Imperatori M., Intagliata S., Vincenzi B., Marchetti P., Papapietro N., Denaro V., Tonini G., Santini D. Premetastatic niche: ready for new therapeutic interventions. Expert Opin. Ther. Targets 2012, 16(Suppl. 2):S119-129.
202. Carlini M.J., De Lorenzo M.S., Puricelli L. Cross-talk between tumor cells and the microenvironment at the metastatic niche. Curr. Pharm. Biotechnol. 2011, 12:1900-1908.
203. Liersch R., Hirakawa S., Berdel W.E., Mesters R.M., Detmar M. Induced lymphatic sinus hyperplasia in sentinel lymph nodes by VEGF-C as the earliest premetastatic indicator. Int. J. Oncol. 2012, 41:2073-2078.
204. Mattila M.M., Ruohola J.K., Karpanen T., Jackson D.G., Alitalo K., Harkonen P.L. VEGF-C induced lymphangiogenesis is associated with lymph node metastasis in orthotopic MCF-7 tumors. Int. J. Cancer 2002, 98:946-951.
205. den Eynden GG Van, Vandenberghe M.K., van Dam P.J., Colpaert C.G., van Dam P., Dirix L.Y., Vermeulen P.B., Van Marck E.A. Increased sentinel lymph node lymphangiogenesis is associated with nonsentinel axillary lymph node involvement in breast cancer patients with a positive sentinel node. Clin. Cancer Res. 2007, 13:5391-5397.
206. Rinderknecht M., Detmar M. Tumor lymphangiogenesis and melanoma metastasis. J. Cell. Physiol. 2008, 216:347-354.
207. Wang X.L., Fang J.P., Tang R.Y., Chen X.M. Different significance between intratumoral and peritumoral lymphatic vessel density in gastric cancer: a retrospective study of 123 cases. BMC Cancer 2010, 10:299.
208. Jakob C., Aust D.E., Liebscher B., Baretton G.B., Datta K., Muders M.H. Lymphangiogenesis in regional lymph nodes is an independent prognostic marker in rectal cancer patients after neoadjuvant treatment. PLoS One 2011, 6:e27402.
209. He Y., Kozaki K., Karpanen T., Koshikawa K., Yla-Herttuala S., Takahashi T., Alitalo K. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J. Natl. Cancer Inst. 2002, 94:819-825.
210. Spano D., Zollo M. Tumor microenvironment: a main actor in the metastasis process. Clin. Exp. Metastasis 2012, 29:381-395.
211. Doan P.L., Chute J.P. The vascular niche: home for normal and malignant hematopoietic stem cells. Leukemia 2012, 26:54-62.
212. Corselli M., Chin C.J., Parekh C., Sahaghian A., Wang W., Ge S., Evseenko D., Wang X., Montelatici E., Lazzari L., Crooks G.M., Peault B. Perivascular support of human hematopoietic stem/progenitor cells. Blood 2013, 121:2891-2901.
213. Lai C.Y., Schwartz B.E., Hsu M.Y. CD133+ melanoma subpopulations contribute to perivascular niche morphogenesis and tumorigenicity through vasculogenic mimicry. Cancer Res. 2012, 72:5111-5118.
214. Ritchie K.E., Nor J.E. Perivascular stem cell niche in head and neck cancer. Cancer Lett. 2012, Epub ahead of print, PMID: 22842095, http://dx.doi.org/10.1016/j.canlet.2012.07.025.
215. Lukanidin E., Sleeman J.P. Building the niche: the role of the S100 proteins in metastatic growth. Semin. Cancer Biol. 2012, 22:216-225.
216. Burgos-Ojeda D., McLean K., Bai S., Pulaski H., Gong Y.S., Silva I., Skorecki K., Tzukerman M., Buckanovich R.J. A novel model for evaluating therapies targeting human tumor vasculature and human cancer stem-like cells. Cancer Res. 2013, 73:3555-3565.
217. Wang S.E., Yu Y., Criswell T.L., Debusk L.M., Lin P.C., Zent R., Johnson D.H., Ren X., Arteaga C.L. Oncogenic mutations regulate tumor microenvironment through induction of growth factors and angiogenic mediators. Oncogene 2010, 29:3335-3348.
218. Felsher D.W. Reversing cancer from inside and out: oncogene addiction, cellular senescence, and the angiogenic switch. Lymphat. Res. Biol. 2008, 6:149-154.
219. Chen C., Cai S., Wang G., Cao X., Yang X., Luo X., Feng Y., Hu J. c-Myc enhances colon cancer cell-mediated angiogenesis through the regulation of HIF-1alpha. Biochem. Biophys. Res. Commun. 2013, 430:505-511.
220. Sodir N.M., Swigart L.B., Karnezis A.N., Hanahan D., Evan G.I., Soucek L. Endogenous Myc maintains the tumor microenvironment. Genes Dev. 2011, 25:907-916.
221. Foy K.C., Liu Z., Phillips G., Miller M., Kaumaya P.T. Combination treatment with HER-2 and VEGF peptide mimics induces potent anti-tumor and anti-angiogenic responses in vitro and in vivo. J. Biol. Chem. 2011, 286:13626-13637.
222. Lirdprapamongkol K., Chiablaem K., Sila-Asna M., Surarit R., Bunyaratvej A., Svasti J. Exploring stemness gene expression and vasculogenic mimicry capacity in well- and poorly-differentiated hepatocellular carcinoma cell lines. Biochem. Biophys. Res. Commun. 2012, 422:429-435.
223. Zhu P., Ning Y., Yao L., Chen M., Xu C. The proliferation, apoptosis, invasion of endothelial-like epithelial ovarian cancer cells induced by hypoxia. J. Exp. Clin. Cancer Res. 2010, 29:124.
224. Comito G., Calvani M., Giannoni E., Bianchini F., Calorini L., Torre E., Migliore C., Giordano S., Chiarugi P. HIF-1alpha stabilization by mitochondrial ROS promotes Met-dependent invasive growth and vasculogenic mimicry in melanoma cells. Free Radic. Biol. Med. 2011, 51:893-904.
225. Sun T., Sun B.C., Zhao X.L., Zhao N., Dong X.Y., Che N., Yao Z., Ma Y.M., Gu Q., Zong W.K., Liu Z.Y. Promotion of tumor cell metastasis and vasculogenic mimicry by way of transcription coactivation by Bcl-2 and Twist1: a study of hepatocellular carcinoma. Hepatology 2011, 54:1690-1706.
226. Sun W., Shen Z.Y., Zhang H., Fan Y.Z., Zhang W.Z., Zhang J.T., Lu X.S., Ye C. Overexpression of HIF-1alpha in primary gallbladder carcinoma and its relation to vasculogenic mimicry and unfavourable prognosis. Oncol. Rep. 2012, 27:1990-2002.
227. Vartanian A.A. Signaling pathways in tumor vasculogenic mimicry. Biochemistry (Mosc) 2012, 77:1044-1055.
228. Seftor R.E., Hess A.R., Seftor E.A., Kirschmann D.A., Hardy K.M., Margaryan N.V., Hendrix M.J. Tumor cell vasculogenic mimicry: from controversy to therapeutic promise. Am. J. Pathol. 2012, 181:1115-1125.